STOCK TITAN

ACADIA PHARMACEUTICALS (NASDAQ: ACAD) officer sells shares for RSU tax withholding

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

ACADIA PHARMACEUTICALS principal accounting officer James Kihara exercised and vested equity awards and sold shares to cover taxes. On May 1, 2026, he exercised 2,596 restricted stock units, receiving the same number of common shares at $0.00 per share. On May 4, 2026, 1,332 common shares were sold at a weighted average price of $21.79, with footnotes stating these mandatory sales were solely to cover withholding taxes and tax-related items in connection with the RSU vesting and intended to meet Rule 10b5-1(c) requirements. After these transactions, he directly held 29,129 common shares.

Positive

  • None.

Negative

  • None.
Insider Kihara James
Role PRINCIPAL ACCOUNTING OFFICER
Sold 1,332 shs ($29K)
Type Security Shares Price Value
Sale Common Stock 1,332 $21.79 $29K
Exercise Restricted Stock Units 2,596 $0.00 --
Exercise Common Stock 2,596 $0.00 --
Holdings After Transaction: Common Stock — 29,129 shares (Direct, null); Restricted Stock Units — 2,596 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.79 to $21.815, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. The restricted stock units vest in four equal annual installments beginning May 1, 2024.
Shares sold for taxes 1,332 shares at $21.79 Mandatory tax-related sale on May 4, 2026
RSUs converted 2,596 units at $0.00 Restricted stock units converting to common shares on May 1, 2026
Shares held after transactions 29,129 shares Direct common stock holdings following reported transactions
Price range of sales $21.79–$21.815 Weighted-average sale price range for 1,332 shares sold
Restricted Stock Units financial
"The restricted stock units vest in four equal annual installments beginning May 1, 2024."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
withholding taxes financial
"mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items"
Withholding taxes are amounts a payer or government takes out of payments — such as wages, interest, or dividends — before the recipient gets the money, functioning like a cashier keeping part of a bill to pay taxes on your behalf. For investors this matters because it reduces the cash they actually receive, affects net returns and yield calculations, and may require additional paperwork or treaty claims to recover or offset the withheld amount against final tax bills.
Rule 10b5-1(c) regulatory
"it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act"
Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kihara James

(Last)(First)(Middle)
C/O ACADIA PHARMACEUTICALS INC.
12830 EL CAMINO REAL, SUITE 400

(Street)
SAN DIEGO CALIFORNIA 92130

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
ACADIA PHARMACEUTICALS INC [ ACAD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
PRINCIPAL ACCOUNTING OFFICER
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/01/2026M2,596A(1)30,461D
Common Stock05/04/2026S(2)1,332D$21.79(3)29,129D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)05/01/2026M2,596 (4) (4)Common Stock2,596$02,596D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
2. The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.79 to $21.815, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
4. The restricted stock units vest in four equal annual installments beginning May 1, 2024.
/s/ Jennifer J. Rhodes, Attorney-in-Fact05/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did ACAD (ACADIA PHARMACEUTICALS) officer James Kihara report in this Form 4?

He reported an RSU vesting and related share sale for taxes. On May 1, 2026, 2,596 restricted stock units converted into common shares, followed by a 1,332-share sale on May 4, 2026, to cover tax obligations tied to the vesting.

How many ACAD common shares did James Kihara sell and at what price?

He sold 1,332 ACAD common shares at a weighted average price of $21.79. Footnotes explain the shares were sold in multiple trades between $21.79 and $21.815, with full trade-by-trade details available upon request from the company or regulators.

Were James Kihara’s ACAD share sales discretionary or for tax withholding?

The filing states the sales were mandatory to cover withholding taxes and related items. It explains the transactions were made in connection with the vesting of restricted stock units and intended to comply with Rule 10b5-1(c) requirements under the Securities Exchange Act.

How many ACADIA PHARMACEUTICALS shares does James Kihara hold after these transactions?

After the reported transactions, he directly holds 29,129 ACAD common shares. This reflects the net position following the vesting of 2,596 restricted stock units and the separate 1,332-share sale executed to satisfy the associated tax withholding obligations.

What happened to James Kihara’s restricted stock units in this ACAD Form 4?

On May 1, 2026, 2,596 restricted stock units converted into an equal number of ACAD common shares. A footnote states each unit represented a contingent right to receive one share, vesting in four equal annual installments starting May 1, 2024.

Does the ACAD Form 4 mention a Rule 10b5-1 trading plan for these transactions?

Yes, the filing states the mandatory sales were intended to comply with Rule 10b5-1(c)(1)(i)(B). It notes the interpretation is meant to satisfy Rule 10b5-1(c) requirements, indicating a pre-arranged, rules-based framework rather than discretionary trading decisions.